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Objective  To assess the effi   cacy of human placental extract (HPE) in an animal model of rheumatoid arthritis (RA).
Method  We used (i) KRN C57BL/6 TCR transgenic x NOD mice (KBx/N) serum transfer arthritis and (ii) collagen-
induced arthritis (CIA) mice to evaluate the effi   cacy of HPE (1 ul or 100 ul, intra-peritoneal, three times per week) 
on RA. Incidence, severity of arthritis, and hind-paw thickness were quantifi  ed. Joint destruction was analyzed 
using modifi  ed mammographic imaging. Histopathological analysis for infl  ammation, cartilage, and osteoclasts 
was performed using Hematoxylin-eosin (H-E), safranin-O, and tartrate-resistant acidic phosphatase (TRAP). 
ELISAs were used for detection of various cytokines in serum and joint tissue.
Results  Th   ere were no signifi  cant diff  erences in incidence of arthritis, clinical scores of arthritis, and hind-paw 
thickness between HPE-treated and vehicle-treated groups for up to 2 weeks in the KBx/N serum transfer arthritis 
model. Histopathological analysis also showed no diff  erences 2 weeks after treatment. Levels of TNF-α, IL-1β, IL-
6, IL-10, and RANKL in serum and joint tissues were similar in all groups. Furthermore, there were no diff  erences 
in clinical, radiological, and histological parameters between HPE-treated and vehicle-treated group for 3 weeks 
in the CIA model.
Conclusion  Systemic treatment with HPE has no benefi  cial eff  ects on arthritis in animal models of RA. Th  erefore, 
indiscreet use of HPE in RA should be forbidden.
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INTRODUCTION
  Recently, injections using human placental extract (HPE) 
have been used extensively.
1 HPE has various effects 
including regulation of the autonomic nervous system 
and the endocrine system, enhancement of immune 
functions, anti-infl  ammation, elimination of free radicals, 
facilitation of wound recovery, liver detoxication, fatigue 
recovery, and increase in appetite.
2 However, animal 
experiments and clinical studies on HPE are insuffi   cient 
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to scientifically demonstrate a working mechanism, 
an effect on RA, and side effects. In practice, the use of 
HPE has been approved by the Korean Food and Drugs 
Administration only for ‘improvement of menopausal 
disorders’ and ‘liver function improvement and fatigue 
recovery.’ However, cases where HPE has been applied in 
Korea and Japan show that it is considered a panacea, and 
has been applied to improve liver function, and to treat of 
menopausal disorders, menstrual irregularity, menstrual 
pain, infertility, vaginitis, genital insuffi   ciency, asthenia, 
dementia, headache, low back pain, osteoarthritis, frozen 
shoulder, atopic dermatitis, to improve sexual function 
and as therapy for alopecia.
2,3
  Rheumatoid arthritis (RA) is a systemic chronic infl  am-
matory disease as well as a representative autoimmune 
disorder.
4 There are 2 possibilities regarding the effect 
of HPE on RA; it may either improve or exacerbate 
rheumatoid arthritis. First, HPE may improve rheumatoid 
arthritis since it has an anti-inflammatory effect as well 
as the ability to eliminate free radicals and to recover 
from and reconstruct wounds. Some studies actually 
showed that HPE increased growth of chondrocytes and 
repressed damage to cartilage.
5,6 Experiments performed 
using an inflammatory arthritis animal model showed 
that local injection of HPE reduced the symptoms of 
arthritis and the expression of infl  ammatory cytokines.
7 
In prior studies that were conducted, some patients with 
rheumatoid arthritis verifi  ed that placenta-eluted gamma 
globulins have a therapeutic eff  ect.
8,9 On the other hand, 
it is known that the placenta contains various growth 
factors such as hepatocyte growth factor (HGF), nerve 
growth factor (NGF), vascular endothelial growth factor 
(VEGF), placenta growth factor (PlGF), epidermal growth 
factor (EGF), fibroblast growth factor (FGF), insulin 
like growth factor (IGF) and transforming growth factor 
(TGF).
2 Among these, VEGF and PIGF are particularly 
well known as representative substances that exacerbate 
rheumatoid arthritis,
10-13 supporting the possibility that 
HPE may exacerbate rheumatoid arthritis. However, no 
study has been conducted on the systemic injection of 
HPE on rheumatoid arthritis.
  Therefore, we investigated the effect of systemic 
HPE injection on rheumatoid arthritis using two 
representative animal models for rheumatoid arthritis: (i) 
a KBx/N with serum transfer arthritis and (ii) a collagen-
induced arthritis (CIA) model .
MATERIALS AND METHODS
Reagents
  In this study, we used HPE provided by Melsmon 
(Melsmon, Tokyo, Japan). HPE is a liquid agent prepared 
by freezing the villous tissue part of fresh placenta and 
then extracting and purifying it by means of hydrochloric 
acid hydrolysis. The extract contains 100 mg of water-
soluble substances in 2 ml of normal saline solution. 
The identified components are nucleic acid related 
substances such as uracil, adenine, guanine and thymine, 
amino acids such as lysine, alanine, asparagic acid, 
leucine, glutamic acid, glycine, valine, serine, tyrosine, 
phenylalanine, threonine, arginine, proline, cystine, 
methionine, histamine, and minerals such as sodium, 
potassium, magnesium, phosphorus, iron. In this study, a 
stock solution of the HPE agent was diluted with normal 
saline and injected intraperitoneally.
Animal preparation
  For the preparation of the KBx/N serum transfer arthritis 
model, KRN TCR transgenic mice provided by D. Mathis 
and C. Benoist (Harvard Medical School, Boston, USA) 
were first mated with non-obese diabetic (NOD) mice. 
Arthritis began to occur about four weeks after birth in 
KBx/N mice. Blood samples were taken in the eighth 
week when the arthritis was most severe. Serum was 
separated by centrifugation and stored frozen. BALB/
c male mice (Orient Bio Inc., Sungnam, Korea) aged 7-9 
weeks were purchased and grown. KBx/N serum (150 
ul) was intraperitoneally injected into BALB/c male 
mice two times on Day 0 and Day 2 to induce arthritis. 
Experimental animals were divided into three groups: 
Group 1 (n=10) was the control group, to which vehicle 
was administered; Group 2 (n=10) received 1 ul of HPE; 
Group 3 (n=10) received 100 ul of HPE. Administration 
of 1 ul HPE was comparable to a dose of 2 ml, which is 
the recommended therapeutic dose for humans. HPE 
100 ul was the maximum dose that did not lead to any 
deaths or fatal toxicity in the mice in a preliminary test, 
and we gave it as a one-time dose in this experiment. 
Intraperitoneal injection of 1 ul or 100 ul HPE and vehicle 
was given two times per week to all mice, from Day 0 to 
day 14.
  For the preparation of the CIA model, DBA/1 male 
mice (Orient Bio Inc., Sungnam, Korea) aged 7-9 weeks The Eﬀ  ect of HPE on RA in an Animal Model
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were purchased. Bovine-type type II collagen (Chondrex 
inc., Redmond, USA) (150 μg) and the same quantity 
of complete Freund’s adjuvant (CFA) (Chondrex inc., 
Redmond, USA) were injected intradermically through 
the tail. Twenty one days later, bovine-type type II 
collagen (150 μg) and the same quantity of incomplete 
Freund’s adjuvant (IFA, Chondrex) were injected through 
the tail to induce arthritis. The experimental animals 
were divided into two groups. Group 1 (n=8), which was 
the control group, was administered vehicle; Group 2 
(n=8) received 1 ul of HPE. Intraperitoneal injection of 
1ul HPE and vehicle was given two times per week to all 
mice from Day 21 to the end of the experiment.
Assessment of arthritis incidence and severity 
  The incidence and severity of arthritis were assessed 
macroscopically by observing mice two or three times 
per week. Th   e severity of arthritis was coded as Grades 0 
to 3 for each leg: Grade 0, without any edema or swelling; 
Grade 1, mild edema and flare localized to the toes or 
ankle joints; Grade 2, moderate edema and flare over 
the ankle joints and toes; and Grade 3, severe edema 
and flare over the region between the ankle joints and 
the entire toes or accompanied by joint stiffness. The 
assessment was performed with reference to the sum of 
the severity measured from the four legs, and thus the 
maximum possible arthritis score was 12 points. The 
presence of arthritis was defined as definite arthritis 
accompanying fl  are and edema together. Th  e  percentage 
(%) of the legs where arthritis occurred among all the 
legs of the subject mouse was recorded as the incidence 
of arthritis. The thickness of the two rear feet was 
measured at the thickest part of the ankles for all mice 
using electronic calipers (Orient Bio Inc., Sungnam, 
Korea). To minimize rater error, arthritis assessment was 
done by two raters who were not aware which were the 
experimental and which the control groups.
Measurement of cytokines in mouse serum and ankle 
tissue
  A mixture of Zoletil (Virbac, Magny-en-Vexin, France) 
and Rumpun (Bayer, Seoul, Korea) was diluted ten times 
with phosphate buffered saline (PBS) and 200 ul of the 
solution was intraperitoneally injected into the mice to 
anesthetize them. Blood samples were then taken by 
cardiocentesis. Serum was separated by centrifugation 
of the blood samples and stored at −70
oC before the test. 
Ankle joint tissues were taken after removing the skin, 
rapidly cooling them with liquid nitrogen, and then 
storing them frozen at −70
oC until use. Ankle tissues 
were ground in a mortar using liquid nitrogen and 
proteins were extracted with a lysis buffer (Mammalian 
Protein Extraction Reagent) (Pierce Biotechnology Inc., 
Rockford, USA) containing proteinase inhibitor cocktail 
(Calbiochem, San Diego, USA). In the serum and joint 
tissue extractions, the cytokine concentrations of TNF-α, 
IL-1β, IL-6, soluble receptor activator of NF-κB ligand 
(sRANKL) and IL-10 were measured using ELISA kits 
(PeproTech inc., Rocky Hill, USA). Th   e capture antibody 
for the cytokine to be measured was put into a 96-
well plate (Nunc, Rochester, USA) for sandwich ELISAs 
and reacted overnight at 4
oC. Then, PBS containing 
the blocking solution (1% bovine serum albumin 
(BSA)/0.05% Tween-20) was added and reacted for two 
hours at room temperature. The standard samples and 
the samples to be measured were reacted for two hours 
at room temperature. After washing them with water, the 
detection antibody was added and reacted for two hours 
at room temperature. Th   en, Avidin-peroxidase (50 μl, 1 : 
2,000) and ABTS substrate solution were added to each 
of the wells one by one and allowed to react. Following 
the reaction, light absorbance was measured at 450 nm 
with an ELISA reader. a standard curve was acquired 
using the concentrations and absorbances of standard 
samples. Then the absorbance of the tested samples 
converted to concentrations using the standard curve. 
Th   e measurement was repeated for all the tested samples 
according to the directions of the manufacturer, and the 
mean values were used for the analysis.
Radiologic assessment
  We performed radiologic assessment to investigate 
the effect of HPE on the degree of  bone destruction. 
Radiological assessments were performed only with the 
CIA model because the KBx/N model, which is a two-
week model, did not show a clear change that could be 
found by general radiological tests since destruction of 
bone was relatively weak.
  The radiography was performed at the knee and ankle 
joints of mice 42 days after the induction of arthritis, 
using a digital mammograph (Mammomat Novation
DR) 
(Siemens, Erlangen, Germany). A full field flat panel Jeong Dong Park, et al.
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digital detector that could create a 24×29 cm image 
(maximum matrix size, 3,328×4,096; pixel size, 70 μm) 
was used, and all the images were taken under exposure 
conditions of 30 kVp, 90 mAs and 1.5 magnifi  cation. Th  e 
destruction of the joints was assessed with respect to the 
region between the patella and the femur and the region 
between the femur and the tibia in case of knee joints; 
and with respect to the three regions of the ankle, the 
intertarsal part and the metatarsophalangeal joint in the 
case of rear foot joints. Joints received scores of Grade 
0 (normal) to grade 5 (complete disruption of the joint) 
(Table 1). Mean radiological scores were determined as 
the mean of the measurements at the respective regions.
Histopathologic assessment 
  Histopathologic assessment was performed 14 days after 
the induction of arthritis in the KBx/N model and 42 days 
after induction in the CIA model.
  For the histopathologic assessment, we took knee and 
ankle joints and prepared paraffin blocks through a 
fixation procedure with formalin and a decalcification 
procedure with Calci-Clear Rapid (Diagnostics, Atlanta, 
USA). Blocks were sectioned into slices of 4 μm thickness 
and attached to slides. After deparaffi   nizing with xylene 
three times, for five minutes each time, we washed the 
slices with distilled water and performed hematoxylin 
and eosin (H&E), Safranine-O and tartate-resistant acid 
phosphatase (TRAP) staining. The progress of arthritis 
was assessed quantitatively with respect to bone erosion, 
pannus formation and cartilage damage. Scores included 
in fi  ve grades between 0 (normal) and 4 (severe) (Table 2).
  In 10 randomly selected zones at 200 X magnification, 
the number of giant cells containing at least three TRAP-
positive nuclei was counted, summed and marked as the 
total number of TRAP-positive cells.
Statistical analysis 
  For comparison of mean values among the groups, a 
Kruskal-Wallis test was performed in the KBx/N model 
and a Mann-Whitney U-test in the CIA model. All the 
results were expressed as ‘mean±standard deviation’ 
Statistical analysis of the data was done using SPSS 
Version 11.0 (SPSS, Chicago, USA). Differences where p 
was less than 0.05 were considered signifi  cant.
RESULTS
Eﬀ  ects of HPE on the KBx/N serum transfer model
  Th   ere was no signifi  cant diff  erence in the incidence of 
arthritis among the three treatment groups (vehicle, HPE 
1 ul, HPE 100 ul). The respective arthritis scores were 
9.11±1.96, 10.22±1.71, and 10.22±1.48 for the first week 
and 5.77±1.30, 6.89±1.90, and 5.89±0.78 in the second 
week (Fig. 1-A, B). There was also no between group 
Table 1. Radiologic Assessment
Grade Bone  erosion
0 Normal
1 1 mild bone erosion
2 2-4 bone erosion at one joint
3 Apparent bone erosion at multiple joint
4 Severe bone erosion at multiple joint
5 Complete disruption of joint
Table 2. Histopathologic Assessment 
Score Infl  ammation Bone erosion
Pannus 
formation
Cartilage damage
0 Normal Normal   
1 Mild Mild, not readily apparent on
 low magnifi  cation
   Mild Mild, with mild (superfi  cial)
 chondrocyte loss and/or collagen
 disruption
2 Moderate Medium, apparent on low
 magnifi  cation
   Moderate Moderate
3 Marked Marked, apparent on low
 magnifi  cation
   Marked Marked
4 Severe Marked erosion/loss with evidence
 of bone remodeling
   Severe Severe diff  useThe Eﬀ  ect of HPE on RA in an Animal Model
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diff  erences in arthritis severity. Th   e thickness of the two 
ankles measured with the electronic calipers in each 
of the mice was 2.61 mm, 2.61 mm, and 2.60 mm in the 
initial stage, 3.59 mm, 3.58 mm, and 3.65 mm in the fi  rst 
week, and 3.06 mm, 3.17 mm, and 3.19 mm in the second 
week in the respective groups (Fig. 1-C). No significant 
diff  erence was found in the improvement or exacerbation 
of arthritis due to HPE. Neither decreased weight nor 
death was found in the 100 ul HPE group (Fig. 1-D).
Effects of HPE on histological findings in the KBx/N 
serum transfer mode
  For histological assessment, we performed H&E and 
Safranine-O staining, and quantitatively assessed 
disease progress in terms of synovial inflammation, 
cartilage damage, and bone erosion. In the vehicle, HPE 
1 ul, and HPE 100 ul groups, the infiltration of synovial 
inflammation cells was 2.83±0.24, 2.36±0.29, and 
2.73±0.41, the cartilage damage was 2.07±0.53, 1.86±0.36, 
and 1.97±0.29, and the bone erosion was 2.33±0.68, 
1.83±0.38, and 2.05±0.45, respectively, indicating that the 
histological fi  ndings were similar to each other (Fig. 2-A, 
B). TRAP staining was done to assess osteoclasts, playing 
a key role in bone erosion in rheumatoid arthritis. The 
results showed no difference in differentiation and 
total number of osteoclasts (Fig. 2-A, C). Similar to 
the macroscopic progressive pattern of the arthritis, 
the histological findings did not show improvement 
or exacerbation of the arthritis due to HPE in terms 
of synovial inflammation, cartilage damage and bone 
erosion.
Fig. 1. Eff  ects of human placental extract (HPE) on arthritis in the KBx/N serum transfer model. (A) Th   e cumulative incidence 
of arthritis during the course of the experiment in vehicle (n=10), HPE 1 ul (n=10), and HPE 100 ul (n=10) treatment groups. Th  e 
severity of arthritis (B), hind-paw thickness measurement (C), and the change of body weight (D) in each group are presented. 
Values presented are the mean±SEM for each experiment.Jeong Dong Park, et al.
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Fig. 2. Th   e histopathological assessment of KBx/N serum transfer arthritic mice treated with human placental extract (HPE). 
(A) Representative H&E staining (upper row, original magnification ×40), safranin O (middle row, ×40), and TRAP (lower 
row, ×400) stained joint tissue sections from vehicle (n=10), HPE 1 ul (n=10), and HPE 100 ul (n=10) treatment groups. (B) 
Histopathological scores of synovial infl  ammation, cartilage damage, and bone erosion in each group. (C) Th   e total number of 
TRAP-positive cells in the fi  eld was counted in each group. Values presented are the mean±SEM. 
Changes in inflammatory cytokines in mouse serum 
and joint tissues 
  At the end of the experiment we measured ,in the serum 
of mice, the concentrations of IL-1β, TNF-α, and IL-6, 
which are important inflammatory cytokines involved 
in the occurrence of rheumatoid arthritis, IL-10, which 
represses chronic infl  ammation in rheumatoid arthritis, 
and sRANKL, which is fundamental to the diff  erentiation 
and activation of osteoclasts . IL-1β and TNF-α were also 
measured at the ankle joints. Serum concentrations of 
IL-1β in the respective groups were 235.38±15.11 pg/
ml, 221.35±19.35 pg/ml, and 224.03±18.22 pg/ml. IL-10 The Eﬀ  ect of HPE on RA in an Animal Model
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concentrations were 204.86±36.20 pg/ml, 186.51±22.36 
pg/ml, and 212.83±55.06 pg/ml. TNF-α concentrations 
were 659.60±249.53 pg/ml, 559.30±151.46 pg/ml, and 
678.45±278.31 pg/ml. IL-6 levels were 566.90±127.04 pg/
ml, 568.80±52.98 pg/ml, and 568.98±144.31 pg/ml, while 
sRANKL concentrations were was 1,472.62±174.03 pg/ml, 
1,323.32±161.28 pg/ml, and 1,410.87±367.16 pg/ml. Th  is 
indicated that there were no decreases in IL-1β, TNF-α, 
IL-6, and sRANKL levels and no increases in IL-10 level 
in groups exposed to HPE. Exacerbation of infl  ammatory 
cytokines was also not found (Fig. 3).
Eﬀ  ects of HPE on the CIA model
  Th   e severity of arthritis was assessed in the CIA model 
where autoimmune arthritis was induced. The arthritis 
scores in the vehicle and HPE administration groups were 
3.75±2.22 and 4.00±1.83 on the 10th day and 6.04±1.91 
and 5.75±1.25 at the end of the experiment, respectively. 
Similar arthritis severity fi  ndings were found for the two 
groups (Fig. 4-A). The ankle thickness in the respective 
groups was 2.94±0.18 mm and 2.91±0.11 mm at the 
beginning of the experiment, 3.31±0.34 mm and 3.58±0.55 
mm on the 10th day, and 4.06±0.53 mm and 4.02±0.42 
mm at the end of the experiment (Fig. 4-B). No signifi  cant 
diff  erence was found in improvement or exacerbation by 
HPE between the two groups. Radiography using digital 
mammography and histopathologic assessment based on 
HE staining, which were done to assess the eff  ect of HPE 
on destruction of bones (which is an important treatment 
goal in rheumatoid arthritis), clearly showed destruction 
of bone in both control and experimental groups (Fig. 
5-A). Th   e mean radiological score of the two groups was 
2.67±0.34 and 2.82±0.25, respectively, indicating that 
bone destruction was mild in both groups (Fig. 5-B). 
Th   e histological analysis scores in the respective groups 
were 3.06±0.20 and 3.22±0.36 for synovial infl  ammation, 
2.27±0.33 and 2.32±0.41 for cartilage damage, and 
2.29±0.28 and 2.48±0.31 for bone erosion, showing no 
improvement or exacerbation by HPE (Fig. 5-A, C).
DISCUSSION
  As placental agents containing various constituents are 
known to have various effects on our bodies, they have 
been used extensively for treatment of various diseases 
for a lengthy period of time.
2,3
  According to the extraction method, HPE may be 
classified into two types: extraction from villous tissue 
and hydrolysates derived from the extraction of the 
whole placenta.
14 At present, only extraction from villous 
tissue is permitted for the improvement of menopausal 
disorders, and only whole placenta for the improvement 
of liver functions.
15 There were two clinical studies in 
Korea conducted on the effect of HPE on menopausal 
disorders. Kong et al.
14 reported that HPE improved 
menopausal symptoms and fatigue in middle aged 
women when compared with the placebo group. Park et 
al.
15 reported a double blind placebo controlled study in 
Fig. 3. Eff  ects of human placental extract (HPE) on cytokines in sera (A) and joint homogenates (B) of KBx/N serum transfer 
arthritic mice. Sera and hind paws were collected at the termination of the experiment (day 14) in vehicle (n=10), HPE 1 ul 
(n=10), and HPE 100 ul (n=10) treatment groups. Th   e concentrations of various cytokines were analyzed by ELISA methods. 
Values presented are the mean±SEM. Jeong Dong Park, et al.
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which HPE improved some menopausal symptoms but 
did not show a significant change in female hormones. 
It is generally accepted that the mechanism of the 
improvement of menopausal disorder symptoms by HPE 
is through the anti-inflammatory effect of HPE.
16-18 The 
anti-inflammatory effect of HPE and the improvement 
in menopausal disorders suggests the possibility that 
HPE has a positive eff  ect on rheumatoid arthritis, which 
is a representative chronic inflammatory disease whose 
incidence is high in menopausal women.
  Rheumatoid arthritis is a systemic inflammatory dis-
ease and a representative autoimmune disease charac-
terized by chronic synovial inflammation, local joint 
destruction and general osteopenia.
4 Some studies have 
investigated changes in the growth of chondrocytes, 
repression of cartilage damage, reduced arthritis 
symptoms and inflammatory cytokine expression due 
to local HPE injection, and the therapeutic effects of 
placenta-eluted gammaglobulins.
5-9 Since rheumatoid 
arthritis is a disease that is invasive to the general joints, 
it is important to investigate the effect of general HPE 
administration. We investigated the eff  ect of general HPE 
administration using two representative rheumatoid 
arthritis animal models. In both of the models, HPE did 
not induce clinical improvement, reduce infl  ammation, 
or reverse destruction of cartilage and bone.
  Since a placenta includes VEGF, PIGF and TNF-α,
10-13  
general administration of HPE may exacerbate rheu-
matoid arthritis. However, the result of our experiment 
did not show any exacerbation with regard to clinical 
progress, infl  ammation, and destruction of cartilage and 
bone. The result of our study showed that the general 
administration of HPE did not have any improving or 
exacerbating effects in rheumatoid arthritis animal 
models. In other words, it is highly probable that cortico-
tropin-releasing factors or immunoglobulins, which may 
have a direct infl  ammatory eff  ect on rheumatoid arthritis 
or VEGF, PIGF, and TNF-α, which may exacerbate 
rheumatoid arthritis, might have been increased or 
decreased in the preparation of the HPE agents. Further 
experiments may need to be conducted to identify the 
above-mentioned substances contained in the HPE 
agents or to investigate the direct eff  ect of the substances 
contained in the HPE on rheumatoid arthritis. 
  The recent study entitled, “Analysis about Consumers 
Use of Human Placental Injection and Development of 
Public Relations Technique,” published by the Korea 
Food and Drug Administration, showed that 80% of HPE 
injections involved misuse or abuse of HPE. Th  e  purpose 
of trying HPE injections was recovery from fatigue 
and improvement of female menopausal symptoms. 
But this occurred in only 23% and 13% of our subjects, 
respectively. On the other hand, 41% of instances of 
HPE use were for skin beauty or whitening; 4% were for 
pain in the joints.
1 One of the reasons why HPE is used 
indiscreetly is insuffi   cient experimental data and clinical 
studies on the effect of HPE injections. In practice, the 
only research data about HPE injections that are available 
in Korea are related to menopausal disorder symptoms. 
Some studies dealt with experiments concerning skin 
Fig. 4. Eff  ects of human placental extract (HPE) on collagen-induced arthritis (CIA). Th   e severity of arthritis (A) and hind-paw 
thickness measurement (B) of CIA mice treated with vehicle (n=8) or HPE 1 ul (n=8). Values presented are the mean±SEM for 
each experiment. The Eﬀ  ect of HPE on RA in an Animal Model
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whitening. Our study is the only report about the eff  ects 
of systemic HPE administration on rheumatoid arthritis. 
Therefore, further systematic and various other studies 
need to be conducted to investigate the eff  ects of HPE on 
various diseases.
CONCLUSION
  We assessed the eff  ect of HPE general administration on 
the incidence rate and severity of rheumatoid arthritis, 
radio  logical bone destruction, cytokine expression 
Fig. 5. The radiological and histopathological assessment of CIA mice treated with human placental extract (HPE). (A) 
Representative radiograph (upper row) and H&E (lower row, original magnifi  cation ×40) of vehicle or HPE injected CIA mice. 
(B) Bone destruction was quantifi  ed in knee and ankle joints from CIA mice in each group. (C) Histopathological scores of 
synovial infl  ammation, cartilage damage, and bone erosion in each group. Values presented are the mean±SEM.Jeong Dong Park, et al.
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in blood and joint tissues, microscopic inflammation 
findings, cartilage damage, and bone erosions in the 
KBx/N serum transfer model and the CIA model which 
are the two representative animal models for rheumatoid 
arthritis. Systemic HPE administration did not show 
any effect on the treatment of rheumatoid arthritis in 
rheumatoid arthritis models involving experimental 
animals. Therefore, the indiscreet use of HPE for RA 
should be forbidden.
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